Reprise Biomedical Email Format
Biotechnology ResearchMinnesota, United States51-200 Employees
Reprise Biomedical develops and commercializes biological medical devices designed to improve tissue healing. The company markets MiroDerm and MiroFlex biologic matrices for wound care and soft tissue reinforcement, and it is leveraging its proprietary perfusion decellularization process to create new devices addressing healing-related surgical needs. Its latest offering, Miro3D wound matrix, provides a three-dimensional approach intended for deep and tunneling wounds. Headquartered in Plymouth, Minnesota, Reprise Biomedical originated in July 2019 as a spin-off from Miromatrix Medical Inc. The firm operates in the biotechnology research sector, focusing on devices that support healing in surgical settings. A notable development in its recent activity is the U.S. launch of Miro3D in October 2022, expanding its wound-management portfolio.